J. David Hansen has served as MabVax’s President, Chief Executive Officer, and Member of its Board of Directors since co-founding MabVax in 2006. Mr. Hansen is a senior corporate executive with diverse and in-depth experience in the biopharmaceutical business. Mr. Hansen has proven leadership abilities in creating, building, and directing small start-up operations and key departments in both large and small biopharmaceutical companies. He has broad therapeutic area expertise including oncology and immunology. He has had direct responsibility for corporate and commercial development functions including in and out licensing, product acquisition, strategic planning and new product planning. From 1998 to 2006, Mr. Hansen was a corporate officer of Avanir Pharmaceuticals. He held the titles of Vice President of Commercial Development, Senior Vice President of Corporate Development, and President and Chief Operations Officer of the Avanir Subsidiary Xenerex Biosciences. From 1989 to 1999 Mr. Hansen served in multiple roles at Dura Pharmaceuticals including National Sales Director, Director of Marketing, and Director of Business Development. He has additional management experience with Merck & Co. (Schering- Plough), Key Pharmaceuticals, and Bristol Myers Squibb.

Recent Posts

Forward Looking Statements

Certain statements contained in this blog are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this blog relate to, among other things, the offering and, expected use of proceeds from the offering. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should'" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this blog. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this blog, except as required by applicable law.

This Blog is official and sanctioned by MabVax Therapeutics, Inc. | See Terms of Use

Get MabVax Therapeutics, Inc. Blog Post Alerts